| A new type of drug: IgE inhibitor |
|
A new class of medications called Immunoglobulin E (IgE) inhibitors is available to treat allergy-related asthma. Omalizumab (Xolair) was the first approved therapy to target the IgE molecule.
It is normal for your airways to tighten and become inflamed if you inhale a dangerous substance. This reaction is an attempt by your body to prevent the threat from traveling too far into your lungs. The airways open up again when the threat has passed.
If you have allergy-induced asthma, however, your airways are overly responsive to mild substances called allergens. Your body's response to these triggers leads to blocked airways and the symptoms of asthma.
Most asthma drugs relieve symptoms by simply "blunting" the response to an asthma trigger. In contrast, IgE blockers actually prevent the response from occurring in the first place.
To understand this more fully, it helps to know what makes something an asthma trigger. If you have an allergy to a substance like pollen, mold, or dust mites (all called allergens), your body makes too many IgE antibodies to that substance. These antibodies recognize and fight against the individual allergens. But, having too many of the IgE antibodies can make the body too responsive to these allergens, and lead to an allergic reaction like asthma.
Xolair binds to excess IgE antibodies in your bloodstream. This stops the IgE antibodies from recognizing the asthma-provoking allergens. In other words, omalizumab stops the body from overreacting to asthma triggers by making the IgE antibodies ineffective. This interrupts the excessive inflammatory response even before it starts. Xolair is given by injection every two to four weeks to prevent asthma flare-ups. Xolair was approved by the FDA in 2003 for patients ages 12 and older with moderate-to-severe persistent asthma. The most common side effect is an injection-site rash.
IgE inhibitors also holds promise for the treatment of other forms of allergic disease.
 |
|
Reviewed By: Alan Greene, M.D., F.A.A.P., Department of Pediatrics, Packard Children's Hospital, Stanford University School of Medicine; Chief Medical Officer, A.D.A.M., Inc., and Jacqueline A. Hart, M.D., Department of Internal Medicine, Newton-Wellesley Hospital, Boston, Ma.
